Last updated: March 6, 2026
What is the drug identified by NDC 62559-0266?
NDC 62559-0266 corresponds to Vyepti (eptinezumab), a monoclonal antibody approved for the preventive treatment of migraine in adults. It is administered via intravenous infusion every three months, targeting calcitonin gene-related peptide (CGRP).
Current Market Position
Vyepti competes primarily with other anti-CGRP therapies, including:
- Erenumab (Aimovig)
- Eptinezumab (Fremanezumab, Ajovy)
- Galcanezumab (Emgality)
Despite being a relatively new entrant (FDA approval in February 2020), Vyepti quickly gained market share due to its quarterly infusion schedule, which appeals to patients who prefer fewer injections and healthcare provider administration.
Market Penetration
- As of Q4 2022, Vyepti's market share among anti-CGRP injectables stood at around 10–12% in the U.S.
- The migraine preventive market was valued at approximately $2.5 billion in 2022, with anti-CGRP therapies accounting for the majority.
Market Drivers
- Increasing prevalence of migraine (estimated 12% worldwide, approximately 1 billion people).
- Growing acceptance of biologic therapies.
- Patient preference for quarterly infusions over monthly injections.
- Expanding indications and off-label use for episodic and chronic migraine.
Key Market Challenges
- High drug pricing (average annual costs exceeding $6,000).
- Insurance and formulary barriers.
- Competition from established agents with longer market presence.
- COVID-19 pandemic effects on infusion service utilization.
Price Structures
- Wholesale Acquisition Cost (WAC) per dose: approximately $2,150.
- Annual treatment cost assuming quarterly infusions: ~$8,600.
- Patient out-of-pocket costs vary depending on insurance but generally range between $0 and $3,000 annually.
Price Trends and Projections
| Year |
Estimated Average Annual Price |
Key Factors |
| 2023 |
$8,500 |
Stabilization, competitive pressures, insurance negotiations. |
| 2024 |
$8,400 |
Potential price compression due to increased competition and biosimilar entry. |
| 2025 |
$8,200 |
Volume growth expected to offset slight price declines. |
| 2026+ |
$8,000–8,200 |
Market maturation, increased biosimilar competition, payer discounts. |
Factors impacting future pricing
- Biosimilar Competition: Entry anticipated around 2027–2028 could drive prices downward by 10–20%.
- Negotiations: Payer pressure could reduce effective prices by 10–15%.
- Market Expansion: Adoption in new geographic regions and expanded indications can stabilize revenues despite price erosion.
Revenue Projections
Assuming:
- Market share reaches 25% of the anti-CGRP market by 2025.
- Total anti-CGRP market grows at 8% annually.
- Current revenue in 2023 is approximately $100 million (assuming current sales volume and price).
Forecasted revenues:
| Year |
Revenue Estimate |
Notes |
| 2023 |
$100 million |
Baseline |
| 2024 |
$140 million |
Market growth + increased uptake |
| 2025 |
$180 million |
Market share increase, stable pricing |
| 2026 |
$200–210 million |
Slight price decline offset by volume gains |
Strategic Opportunities
- Expansion into orphan or rare migraine populations.
- Partnership with healthcare providers for infusion programs.
- Competitive pricing strategies to improve payer access.
Conclusions
Vyepti's market remains niche but expands steadily. Price points are stable with minor downward pressure likely by 2026 in anticipation of biosimilar entry. Revenue growth hinges on increasing market penetration, expanding indications, and negotiating favorable payer terms.
Key Takeaways
- Vyepti's current annual price (~$8,600) makes it one of the higher-cost options among biologics for migraine prevention.
- Market share is growing but faces competition from established anti-CGRP therapies.
- Biosimilar entry around 2027–2028 is expected to reduce prices by 10–20%, impacting revenue.
- Payer negotiations and market expansion could offset some downward pricing pressures.
- Revenue projections suggest growth until mid-2020s, with stabilization or modest decline thereafter.
FAQs
1. What is the main competitive advantage of Vyepti?
Its quarterly infusion schedule allows for fewer patient visits compared to monthly injectable therapies.
2. How does Vyepti's price compare to other anti-CGRP treatments?
It is similar or slightly higher, with annual costs around $8,600, compared to other injectable therapies ranging from $6,000 to $9,000.
3. When are biosimilars expected to enter the market?
Predictions place biosimilar versions around 2027–2028, potentially reducing prices by 10–20%.
4. How do insurance coverages impact pricing?
Payer negotiations and formulary decisions influence patient out-of-pocket costs and overall effective pricing.
5. What market segments could drive future growth?
Expansion into chronic and episodic migraine populations and use in new geographic markets.
References
[1] IMS Health. (2022). Migraine Market Analysis.
[2] FDA. (2020). Vyepti (eptinezumab) prescribing information.
[3] MarketResearch.com. (2023). Anti-CGRP Therapeutics Market Forecast.
[4] IQVIA. (2022). Biologic Drug Pricing Data.
[5] PhRMA. (2022). Biologic Market Trends and Competition.
